Soligenix, Inc. — Q2 2017 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2017. Soligenix is a late-stage biopharmaceutical company developing rare-disease therapies across BioTherapeutics and Vaccines/BioDefense. Revenue is primarily reimbursement under government contracts.
Financial performance and position
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Contract revenue | $991,000 | $3,160,000 | $2,322,000 | $5,791,000 |
| Gross profit (margin) | $314,000 (32%) | $818,000 (26%) | $557,000 (24%) | $1,216,000 (21%) |
| Research and development | $1,784,000 | $828,000 | $3,001,000 | $2,256,000 |
| Operating loss | $2,317,000 | $1,010,000 | $4,055,000 | $2,916,000 |
| Net loss | $2,312,000 | $93,000 | $4,045,000 | $1,242,000 |
- Six-month operating cash outflow was $2,980,000, versus $2,352,000 in 2016. Cash and cash equivalents declined to $5,814,000 from $8,773,000 at December 31, 2016.
- Working capital was $3,506,000, down from $7,244,000. Total assets were $6,774,000 and shareholders’ equity was $3,622,000 at June 30, 2017.
- The balance sheet reports $3,152,000 of current liabilities and no notes payable at June 30, 2017. The previously issued notes were repaid in 2016.
- Basic and diluted loss per share were $0.41 for Q2 and $0.73 for the six-month period. Potentially dilutive warrants and options were excluded where anti-dilutive.
Material changes and business developments
- Revenue fell 69% in Q2 and 60% for the six-month period, primarily because the NIAID OrbeShield contract was completed and BARDA did not extend its contract beyond the base period. Vaccines/BioDefense generated all reported contract revenue.
- R&D expense rose 115% in Q2 and 33% for six months, reflecting preparation and initiation of the SGX942 Phase 3 trial and continued SGX301 Phase 3 spending. G&A expense declined 15% and 14%, respectively.
- Comparative 2016 net results included non-cash warrant-liability fair-value income of $525,000 for Q2 and $1,285,000 for six months, plus $391,000 of reversed accrued expense. The warrants were reclassified to equity in 2016; these items contributed to the substantial year-over-year increase in reported losses.
- Management’s stated program priorities include completing enrollment and reporting preliminary results from the SGX301 Phase 3 trial, advancing SGX942 Phase 3, and pursuing RiVax and other funded programs. SGX203 Phase 3 is contingent on additional funding.
Outlook, liquidity, and risks
- Management expects approximately $10.8 million of R&D spending over the next 12 months before contract reimbursements, including $6.7 million for BioTherapeutics and $4.1 million for Vaccines/BioDefense; it anticipates approximately $4.1 million of related contract revenue.
- Management said available cash and expected funding sources should cover anticipated working-capital and capital needs for at least the next 12 months, and its approved budget indicated funding through at least September 30, 2018. These estimates depend on spending controls, government contracts and grants, New Jersey NOL-sale proceeds, financing, and other funding sources.
- The company disclosed up to $16.3 million of active government contract funding, subject to agency options and termination rights, and $10.3 million remaining under its Lincoln Park equity facility, which expires in March 2019. No assurance is given that these or partnership and grant funding will be realized.
- On August 11, 2017, after quarter-end, Soligenix entered an at-the-market equity sales agreement for up to $4.8 million in gross proceeds. It is not required to sell shares; FBR’s commission is 3% of proceeds. Any sales would dilute existing shareholders.
- Other obligations include $450,000 of licensing commitments, $127,500 of lease commitments, and potential success-based milestones of up to $7.9 million plus royalties up to 6% of covered-product net sales. A separate hypericin asset agreement provides for up to $10 million in additional milestone payments if achieved; none had been paid or accrued.
- Key risks include sustained losses and reliance on external funding, uncertain government-contract renewals, clinical and regulatory execution, and the possibility that planned financings or partnerships may not be available on favorable terms. Management reported disclosure controls effective at the reasonable-assurance level and no material quarterly change in internal control over financial reporting.
Most important facts for investors to verify
- Actual cash burn, trial costs, and whether funding assumptions support management’s stated runway.
- Enrollment and results timing for SGX301 Phase 3 and progress of the SGX942 Phase 3 trial.
- Renewal or replacement of government funding after the BARDA base period and NIAID contract completion.
- Use of the Lincoln Park facility or the new $4.8 million ATM program, including resulting share dilution.
- Whether funding is secured for SGX203 and other programs described as contingent on additional support.